Third Circuit Affirms Lone Pine Order and Ensuing Dismissals in In re Zostavax MDL

Start
In March 2022, the In re Zostavax MDL court entered a Lone Pine order requiring plaintiffs who claimed to have developed shingles as a result of using the Zostavax vaccine to produce certain test results supporting causation. In December 2022, the court dismissed 1,189 cases for failure to comply with that Lone Pine order……
By: Faegre Drinker Biddle & Reath LLP
Previous Story

Coastal Plains Community MHMR Center Announces Data Breach

Next Story

FDA’s Second Untitled Letter of the Year – An Apparently Tough Choice Between Raising Awareness and Public Safety for Anaphylaxis Drugs